Eight-week Effect of the Sit-to-stand Test on Muscle Architecture.

February 27, 2023 updated by: Rodrigo Lizama Perez, Universidad de Granada

Effect of the Sit to Stand Test on Muscle Architecture After Eight Weeks.

An 8-week intervention of the sit-to-stand test (STS) of 5 and 10 repetitions will be performed to two randomly selected groups to compare its effect on the muscle architecture of the vastus lateralis muscle.

H1: 10 STS significantly modifies vastus lateralis muscle architecture in adults compared to 5STS and the control group.

Study Overview

Detailed Description

Participants will be required to attend the laboratory for a first familiarization visit, where descriptive, biometric, and medical variables will also be evaluated. In addition, during this first familiarization session, it will be previously determined if the participants present any exclusion criteria and their muscle architecture will also be evaluated. After the familiarization session and the participants have signed the informed consent form, they will be randomly assigned to a 5 STS, 10 STS, or control group. Each group (exception of the control group) will be asked to perform three times a week one of the STS modalities assigned to them for 8 weeks, to ensure that the test is completed correctly and also to maintain the planning, the evaluator will be connected virtually with the participants, where rest times will be controlled and a fatigue perception scale will be performed at the end of each session, which will allow controlling the process each session. Subsequently, participants will be asked to attend the laboratory to re-evaluate their architectural parameters ( pennation angle, fascicle length, and muscle thickness) of the quadriceps muscle, one week after performing the intervention.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Grupo de Investigación IDAFISAD 642 Universidad de Granada

Study Locations

      • Valdivia, Chile, 50900000
        • Universidad San Sebastián, sede Valdivia.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults, over 18 years of age.
  • They must have signed the informed consent form.
  • Who can perform the STS.
  • In case of suffering from a chronic non-communicable disease, that it is under control.

Exclusion Criteria:

  • Inability to perform the STS.
  • Hypertension (>200/110 mmHg).
  • Acute neuromuscular or joint injury.
  • Who have suffered a stroke in the last 6 months.
  • Who have suffered a myocardial infarction or fracture in the last 6 months.
  • Terminally ill.
  • People who practice a sport professionally.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group 5 STS
Group 5 STS will perform the same protocol as group 10 STS, only the number of repetitions between each set will change.

For 8 weeks, 3 times per week and 3 sets of 5 repetitions during the first month, then 5 sets of 5 repetitions during the second month.

Between each repetition, there will be a rest of 30 to 60 seconds approximately.

Experimental: Group 10 STS
Group 10 STS will perform the same protocol as group 5 STS, only the number of repetitions between each set will change.

For 8 weeks, 3 times per week and 3 sets of 10 repetitions during the first month, then 5 sets of 10 repetitions during the second month.

Between each repetition, there will be a rest of 30 to 60 seconds approximately.

No Intervention: Control group
Control group, no intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the pennation angle of the vastus lateralis muscle.
Time Frame: Before, 1 week completion of the intervention.
Calculated as the angle of insertion of the muscle fiber fascicles into the deep aponeurosis, measured with a linear probe in B-mode.
Before, 1 week completion of the intervention.
Change in the length of the fascicle of the vastus lateralis muscle
Time Frame: Before, 1 week after completion of the intervention.
is calculated by measuring the length of the fascicular pathway between the superficial and deep aponeuroses,measured with a linear probe in B-mode.
Before, 1 week after completion of the intervention.
Change in vastus lateralis muscle thickness
Time Frame: Before, 1 week after completion of the intervention.
Muscle thickness will be determined as the distance between the superficial aponeurosis to the deep aponeurosis, measured with a linear probe in B-mode.
Before, 1 week after completion of the intervention.
Change in muscle quality index (MQI)
Time Frame: Before, 1 week after completion of the intervention.
Was calculated using two different formulas: one proposed by Takai et al. And one by Fragala et al. The "Takai formula" considers the time required to perform ten repetitions of the sit-to-stand test, while the "Fragala formula" uses the time required for five repetitions: MQI = ((leg length x chair height) x body mass x gravity x 10/ Time STS). Both calculations consider the length of the leg in meters, the height of the chair used in the test, body mass in kilograms, acceleration due to gravity (9.81 m/s^2), and a fixed constant of 10.
Before, 1 week after completion of the intervention.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in STS mean velocity (m· s-1), STS mean force (N), STS mean power (W), and STS relative power (W·Kg-1)
Time Frame: Before, 1 week after completion of the intervention.

The STS mean velocity (m· s-1), STS mean force (N), STS mean power (W), and STS relative power (W·Kg-1), were calculated with the formulas proposed by Alcazar et al. The formulas are as follows:

  1. STS mean velocity = [0.5 x Height - Chair height] / Five STS time × 0.1]
  2. STS mean force = 0.9 x g x Body mass
  3. STS mean power = Body mass x 0.9 x g x [Height x 0.5 - Chair height / Five STS time × 0.1]
  4. Relative STS mean power = 0.9 x g x Height [ 0.5 x Chair height] / Five STS time × 0.1]
Before, 1 week after completion of the intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rodrigo Lizama Pérez, M.Sc, Universidad de Granada

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 8, 2022

Primary Completion (Actual)

December 10, 2022

Study Completion (Actual)

February 15, 2023

Study Registration Dates

First Submitted

July 19, 2022

First Submitted That Met QC Criteria

July 19, 2022

First Posted (Actual)

July 21, 2022

Study Record Updates

Last Update Posted (Actual)

March 2, 2023

Last Update Submitted That Met QC Criteria

February 27, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • IDAFISAD 64201

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on Group 5 STS

3
Subscribe